
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics Inc has demonstrated robust revenue growth, with a 21% increase in international osteoarthritis pain revenue and a remarkable 25% growth in its regenerative solutions segment, driven largely by the successful Integrity patch product. The company is also forecasting a significant expansion in procedures and revenue related to Integrity in 2025, bolstered by further opportunities to enhance utilization among current customers and broaden its market reach. Additionally, positive trends in free cash flow and potential improvements in gross margins indicate strengthening operational efficiency, particularly as production issues resolve, which supports a favorable long-term financial outlook.
Bears say
Anika Therapeutics Inc reported a 5.9% decline in revenue, generating $27.8 million, which underscores persistent challenges in maintaining top-line growth amidst ongoing production yield issues. The company's gross margin of 56% fell short of expectations, and the failure of the pivotal FastTrack trial for Hyalofast raises concerns about the effectiveness of its clinical programs, essential for long-term revenue generation. Additionally, significant anticipated declines in Anika's OEM channel revenue, coupled with mixed performance in adjusted EBITDA, contribute to a negative outlook on the company's financial health.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares